Novartis Diovan scandal claims two more papers
A complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other. Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of … Continue reading Novartis Diovan scandal claims two more papers